MC
TEVA icon

Maverick Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Maverick Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,300,520
Closed -$86.9M – 252
2025
Q3 		$86.9M Sell
4,300,520
-77,170
-2% -$1.36M 1.16% 27
2025
Q2 		$73.4M Buy
4,377,690
+4,347,398
+14,352% +$70.2M 1.1% 28
2025
Q1 		$466K Buy
30,292
+16,137
+114% +$288K 0.01% 226
2024
Q4 		$312K Sell
14,155
-54,624
-79% -$994K 0.01% 183
2024
Q3 		$1.24M Buy
68,779
+3,296
+5% +$57.7K 0.02% 184
2024
Q2 		$1.06M Buy
65,483
+7,938
+14% +$122K 0.02% 210
2024
Q1 		$812K Sell
57,545
-5,502
-9% -$69.4K 0.02% 152
2023
Q4 		$658K Buy
63,047
+29,942
+90% +$280K 0.01% 163
2023
Q3 		$338K Sell
33,105
-17,483
-35% -$163K 0.01% 210
2023
Q2 		$381K Sell
50,588
-2,277
-4% -$18.5K 0.01% 301
2023
Q1 		$468K Buy
52,865
+21,416
+68% +$212K 0.01% 292
2022
Q4 		$287K Buy
+31,449
New +$274K 0.01% 302
2021
Q3 		– Sell
-44,879
Closed -$444K – 793
2021
Q2 		$444K Sell
44,879
-110,962
-71% -$1.17M ﹤0.01% 397
2021
Q1 		$1.8M Buy
155,841
+111,167
+249% +$1.27M 0.02% 162
2020
Q4 		$431K Sell
44,674
-80,503
-64% -$771K 0.01% 386
2020
Q3 		$1.13M Buy
+125,177
New +$1.32M 0.02% 254
2020
Q1 		– Sell
-461,715
Closed -$4.53M – 541
2019
Q4 		$4.53M Sell
461,715
-199,500
-30% -$1.78M 0.07% 150
2019
Q3 		$4.55M Buy
+661,215
New +$5.07M 0.07% 173
2019
Q2 		– Sell
-94,530
Closed -$1.48M – 341
2019
Q1 		$1.48M Sell
94,530
-146,690
-61% -$2.59M 0.02% 255
2018
Q4 		$3.72M Buy
+241,220
New +$4.95M 0.05% 212

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Maverick Capital's TEVA Position: Q4 2025 in Review

Maverick Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 4,300,520 shares — an estimated $86.9M sold.

Maverick Capital first reported a position in TEVA in Q4 2018 and held it in 20 quarters. The position peaked at $86.9M in Q3 2025. 629 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Maverick Capital reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Maverick Capital sold 4,300,520 Teva Pharmaceuticals shares in Q4 2025, an estimated $86.9M.
  • Maverick Capital first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 20 quarters.
  • Maverick Capital's Teva Pharmaceuticals position peaked at $86.9M in Q3 2025.
  • 629 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Maverick Capital's 13F filing for Q4 2025, filed 13 Feb 2026.